Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections
MetadataShow full item record
CitationDalli, Jesmond, Nan Chiang, and Charles N. Serhan. 2015. “Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections.” Nature medicine 21 (9): 1071-1075. doi:10.1038/nm.3911. http://dx.doi.org/10.1038/nm.3911.
AbstractEndogenous mechanisms leading to host protection and resolution of infections without immunosuppression are of wide interest1,2. Here we elucidated the structures of four new host-protective molecules produced in neutrophil-endothelial co-cultures, and present in human and mouse tissues after sterile inflammation or infection. These bioactive molecules contained conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5). These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during Escherichia coli infections. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. The actions of atorvastatin and RvT were additive in E. coli infections in mice where they accelerated resolution of inflammation and increased survival >60%. These results document novel host protective molecules in bacterial infections, namely 13-series resolvins, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. These novel molecules regulate key innate protective responses in the resolution of infectious-inflammation.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318587
- HMS Scholarly Articles